IL1B and lung carcinoma: Recently, the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial incidentally demonstrated that inhibiting IL-1β is associated with a significantly reduced incidence and mortality of lung cancer [5].